

Scientific contributions at AMCP

Presentation:

Hogue SL, Silvia S, **Hollis K**. EPIPEN4SCHOOLS® survey combined analysis: staff training and use of epinephrine auto-injectors.

Posters:

Dhamane AD, **Candrilli SD**, **Meyers J**, Luthra R, Kaila S. Initial diagnosis and treatment patterns by healthcare setting among Chronic Obstructive Pulmonary Disease (COPD) patients in the United States.

Candrilli S. Health care resource utilization associated with tympanostomy tube placement in pediatric populations.

Graham J, **Xuan D**, Luthra R, Borker R, **Earnshaw SE**, Lim J. Budget impact analysis of afatinib for the first-line treatment of metastatic non-small cell lung cancer patients with epidermal growth factor receptor exon 19 deletion mutations in a U.S. health plan.

Waters HC, **Goyal RK**, Strauss L, **Nagar SN**, Wilbanks J. Regional differences in HEDIS measure results for schizophrenia treatment adherence in state Medicaid programs.

Mansfield C, Thomas N, **Gebben D**, **Lucas M**, **Hauber BA**. Differences in preferences for disease-modifying treatments across subgroups of US patients with relapsing multiple sclerosis.


Waters HC, **Goyal RK**, Strauss L, **Nagar SN**, Wilbanks J. Regional differences in HEDIS measure results for schizophrenia treatment adherence in state Medicaid programs.

Contact us today
to learn more:
www.rtihs.org

The power of **knowledge**.
The value of **understanding**.

RTI (h)(s)

Health Solutions



Our expertise to position your product for success.

With so many public, private, and non-traditional payers and their ever-changing priorities, how do you keep up? But, given their role in your success, how do you not?

We can help you navigate the pricing and reimbursement bodies that ultimately determine the accessibility of your product. By engaging with national, regional, and local payers and payer decision makers about your new product, we can help you understand the clinical and economic evidence they will expect to see for it to gain reimbursement.

Let us help you answer critical questions about:

- Payer perspectives and value drivers
- Price value mapping
- Critical pathway and landscape assessments
- Reimbursement issues to address in your value discussions
- Treatment attributes that influence pricing, reimbursement, and access decisions
- Evidence gaps and approaches to fill them

Thursday,
May 12
1:00 pm EDT.

Join us for our **FREE** webinar:
AMCP Dossiers: Latest Guidelines and Best Practices

- Get a summary of the latest AMCP Format, Version 4.0
- See a comparison of the major differences between AMCP Format Versions 3.1 and 4.0
- Learn recommended best practices for preparing AMCP dossiers using the latest AMCP Format, Version 4.0

Visit rtihs.org/AMCP4.0webinar to register

87

AMCP dossier and dossier update projects in 32 therapeutic areas

86

Experts including current ISPOR Board of Directors member, Josephine Mauskopf, PhD

Over 1,000 combined years of experience in our Health Economics and Market Access and Outcomes Research teams

756

Economic Modeling Projects

- User-friendly, transparent and scientifically rigorous
- Budget impact
- Cost-consequence analyses
- Value-based pricing models
- Field tools, including cost calculators

310

Evidence Generation Projects

- Database Studies
- Retrospective Medical Record Reviews
- Systematic Literature Review
- Meta-analyses and Indirect Treatment Comparisons

90

US Participants on Our Payer Advisory Panel

- Focus groups
- Interviews
- Surveys
- Delphi panels
- Mock pharmacy and therapeutics committees

Interactive Communication Tools

Visually demonstrate your product's value to key stakeholders

- Key product value messages
- Disease burden and unmet need
- Clinical, economic, humanistic, and comparative value
- Top-line objection handling
- FDAMA Section 114 compliant

Payer Advisory Panel

- Senior decision makers including Chief Medical Officer and Pharmacy Director
- Payer research
- Value message testing
- Reimbursement assessment